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The increasing cost of health care delivery, coupled with reduced investments and bud-
get  cuts in European health care systems, has had a severe negative impact on health care
delivery in Spain. This reduction in spending has had particularly negative effects on special-
ties  that are heavily reliant on large capital investments to purchase the latest technologies
needed to deliver optimal radiotherapy treatments. The Spanish Society of Radiation Oncol-
ogy  has been proactively working to mitigate the negative impact of budget cuts in Spain.eywords:
adiation Oncology Management
pain
udgets
echnology
In  this paper, the authors describe a variety of solutions and proposals to overcome these
challenges.
©  2013 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer
Centre.
1.1.  Organization  of  cancer  care  in  Spain.  Introduction
n recent years, health care costs have been rising steadily in
ockstep with the increasing burden of cancer [1]. Although a
arge portion of this increased expense is mostly attributable
o a greater prevalence of cancer in the population due to
emographic and lifestyle factors[2], the role of accelerat-
ng technological change cannot be understated[3,4]. This
ituation is particularly problematic given the simultaneous
ecrease in tax revenues caused by the current economic
risis. The combined effect of rising costs and decreased gov-
rnment spending has had a devastating impact on health
are delivery around Europe[5].
The Spanish health care system is among those countries
ardest-hit by the crisis and investment in health care has
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ttp://dx.doi.org/10.1016/j.rpor.2013.10.002been reduced dramatically[6]. The impact has been espe-
cially notable on specialities such as Radiation Oncology that
depend on heavy capital investments in costly equipment
such as linear accelerators and modern imaging scanners[7].
Despite the difﬁculties posed by the current ﬁnancial prob-
lems, these challenges are not insurmountable. However,
what is needed is a re-thinking of priorities and, perhaps even
a radical new approach to how radiotherapy services are paid
for. In the present article, we  describe some of the most impor-
tant challenges in Radiation Oncology in Spain and suggest
some innovative solutions to overcoming these challenges.as Dr Negrín University Hospital University of Las Palmas, Spain.
Health care in Spain is organised as a National Health System
(NHS)[8], with universal, free coverage for all Spanish citizens.
.o. on behalf of Greater Poland Cancer Centre.
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However, implementation is not uniform, as each of the coun-
try’s 17 autonomous regions controls many  aspects of health
care delivery in their respective regions. Importantly for this
discussion, health care funding is allocated from the central
government, and reductions in the NHS budget affect all 17
regions[8].
Infrastructure and Stafﬁng
1.2.  Infrastructure
According to the International Atomic Energy Association
(IAEA), the recommended equipment coverage for radiothe-
rapy is 6 megavoltage (MV) units per million inhabitants. With
a population of 45 million inhabitants, Spain needs approx-
imately 280 MV  units. Currently, there are 250 MV units in
Spain, 45 of which are more  than 10 years old, and 22 of which
are cobalt 60 machines. Thus, approximately one-third of the
total MV  units in Spain need to be replaced[9].
This equipment replacement, which will undoubtedly
require a heavy investment, should be viewed from at least
two perspectives. First, replacement units are needed to
offer patients the best treatment to improve survival while
decreasing toxicity and other adverse effects. There is little
doubt that replacing outdate linear accelerators (linacs) will
improve outcomes and thereby reduce the costs associated
with suboptimal treatments (e.g., toxicity, hospitalization,
medications, re-treatment, etc.). In addition, more  advanced
equipment would allow us to reduce treatment times, as
radiotherapy can be delivered faster and more  efﬁciently with
modern linacs. This, in turn, would have a positive impact on
overall savings, and there are clear examples in Europe that
demonstrate this[10,11]. For example, the National Institute
of Health in the United Kingdom estimated that 53% of the
total cost of cancer care in 2010 was attributable to indirect
mortality costs, with 8% related to indirect morbidity costs.
These ﬁgures suggest that improvements in treatments and
outcomes will ultimately result in both direct and indirect cost
reductions[12].
However, because the investment required is so great, we
believe that it is essential to develop a national plan to estab-
lish a deﬁned time to renovate equipment on a rational basis. If
such a plan is not developed, we  may ﬁnd ourselves—perhaps
even within a relative short time (3-5 years)—in an extremely
unfortunate situation as radiotherapy equipment around the
country becomes woefully outdated. It is not difﬁcult to imag-
ine the difﬁculties of attempting to replace 100 radiation units
for external beam radiotherapy in a short period of time.
However, this is very likely to occur if we do not push for a
reasonable plan now.
1.2.1.  Rethinking  how  we  pay  for  radiotherapy
In most of the world, the present model of radiotherapy deliv-
ery involves the purchase of equipment from manufacturers
or distributors. When these machines become outdated, they
are replaced by newer machines. However, this approach is
expensive, particularly because technological change is occur-
ring so rapidly that even the latest equipment will be obsolete
within a few years. We  suggest two possible solutions to this
problem.iotherapy 1 8 ( 2 0 1 3 ) 401–404
One simple change would be to avoid purchasing equip-
ment that is not upgradeable. While some accelerators (e.g.,
RapidArc on Varian Trilogy) can be upgraded relatively easily,
this is not always the case. For this reason, it is important to
consider the upgrade possibilities carefully before purchase.
Moreover, even when upgrades are possible, there inevitably
comes a time when older machines become outdated and
must be replaced.
Given this problem of rapid obsolescence, we suggest that
health authorities need to consider a more  radical alternative
to the traditional economic model described above. Instead of
purchasing machines outright, it might make more  sense to
pay on per-treatment basis: that is, each radiotherapy session
or service would have a pre-deﬁned cost paid directly to the
service provider. In this model, the radiotherapy equipment
provider (the manufacturer or specialised provider) would be
responsible for purchasing, maintaining, and replacing the
equipment. While such a change would represent a paradigm
shift that would require a great deal of study and discussion
before it could be implemented, we believe strongly that new
ideas and approaches are urgently needed. Clearly, such a far-
reaching change would require the cooperation of all parties
involved—industry, government, hospitals, and health care
professionals—and this will not be easy to obtain.
Short of achieving the aforementioned paradigm shift in
how radiotherapy is paid for, another obvious approach is to
focus on improving treatment processes—in other words, in
streamlining and increasing efﬁciency to avoid waste, min-
imize errors, and improve outcomes[13]. Certainly, in this
sense, the use of modern, up-to-date technology would be
enormously helpful. However, the approach has to be multi-
dimensional and include all aspects of cancer care delivery. If
properly implemented, a focus on improving quality and efﬁ-
ciency would surely result in better care and outcomes, fewer
treatment-related complications, and greater efﬁciency and
savings[14].
1.3.  Stafﬁng
Another cost-related concern involves human resources. The
increasing prevalence of cancer, coupled with the growing
number of indications for radiotherapy (stereotactic body
radiotherapy [SBRT] for inoperable lung cancer is a good exam-
ple) has stimulated the demand for new specialists. At present,
there is a deﬁcit in the number of Radiation Oncology spe-
cialists at the national level. Currently, the mean number of
specialists per million inhabitants in Spain is approximately
11.5, a ﬁgure that is far below the ratio (20 specialists/million)
recommended by the Spanish Society for Radiation Oncology
(SEOR). These ﬁgures imply that, as a whole, Spain is under-
staffed by 300 to 350 specialists. Moreover, the distribution of
these specialists among the 17 autonomous communities of
Spain is highly uneven.
Unfortunately, current economic conditions and severe
budget restrictions limit the ability to hire new specialists. As
a result, this care deﬁcit is remedied in an ad hoc manner, with
many Radiation Oncologists working overtime without extra
compensation. However, this situation is not sustainable. The
obvious solution is to train and hire more  specialists, although
this may not be possible in the short term. Another solution
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o stafﬁng shortages may be to reallocate responsibilities to
ther professionals (physicists, nurses, radiotherapy technol-
gists, imaging technicians, quality control technicians, etc.).
elegation of certain tasks would allow radiation oncologists
o focus on the core clinical aspects of care and would reduce
he demand for new specialists, at least partially.
Finally, in order to prevent an over or under-supply of spe-
ialists in the future, we  believe that a national “specialist
hortages map” should be created. This map  would be based
n expected demand for new specialists (taking into account
opulation growth, changes in demographics, and changing
ndications for radiotherapy) as well as the expected retire-
ent dates of current professionals. In this way, we could
djust the number of specialists in training to future needs
nd, very likely, save money by avoiding stafﬁng imbalances.
.  The  importance  of  evaluating
ost-effectiveness
hile technological advances are both necessary and wel-
ome, it is essential that we carefully evaluate all new
echnologies to be sure that they offer more  than a marginal
mprovement over existing technologies. The introduction of
ew technologies must be supported by rigorous evidence
o avoid making costly investments without strong evidence
egarding not only the efﬁcacy of these technologies, but also
heir cost-effectiveness[14].
Although our aim should always be to provide the most
fﬁcacious treatments to patients, we must keep in mind that
udgets are not unlimited and therefore the cost-effectiveness
f treatments and equipment is essential. Although manufac-
urers make every effort to convince us of the beneﬁts of their
atest technology[15], these beneﬁts are often either marginal
r unproven[16]. We  must, therefore, carefully weigh the costs
nd beneﬁts before purchasing new equipment[17].
In some cases, newer technologies undoubtedly reduce the
irect and indirect costs of treatment by improving tumour
ontrol (e.g., SBRT in lung cancer), reducing toxicity (e.g.,
ntensity-modulated radiotherapy in head & neck cancer)
nd/or shortening the course of treatments (e.g., hypofrac-
ionated radiotherapy). All of these beneﬁts may decrease the
ndirect costs of cancer care, including factors related to lost
ime and productivity.
The SEOR is working diligently to resolve the issues dis-
ussed in this paper. One approach that we have taken is to
rganize meetings that include the department heads (and
taff members with managerial responsibilities) of all Radi-
tion Oncology services in Spain. Similarly, the SEOR has
reated working groups at the national level to establish com-
on  ground with all of the professional agents involved in
ancer care delivery.
.  Conclusions
he economic crisis should not be the cause of inequitable
reatment of patients, who should all have equal access to
he most appropriate treatment for their particular tumour.
ikewise, the crisis should not be a cause for professional
espondency. In times of profound crisis all of us—health
[1therapy 1 8 ( 2 0 1 3 ) 401–404 403
authorities, equipment manufacturers, the pharmaceutical
industry, health care professionals, and society—need to work
together to develop a shared commitment to ﬁnding solutions
to our problems.
Conﬂic  of  interest
None declared.
Financial  disclosure
None declared.
Acknowledgements
The authors with to thank Bradley Londres for his excellent
assistance in improving the English language in this article.
 e  f  e  r  e  n  c  e  s
1]. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ,
Amir E, et al. Delivering affordable cancer care in
high-income countries. Lancet Oncol 2011;12:933–80.
2]. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global
cancer statistics. CA-CANCER J CLIN 2011;61:69–90.
3]. Barbash GI, Glied SA, New Technology. Health Care Costs —
The Case of Robot-Assisted Surgery. NEJM 2010;363:701–4.
4]. Njeh CF, Langton CM, Orton CG. The adoption of new
technology in radiation oncology should rely on
evidence-based medicine. Med Phys 2011;38:2825.
5]. Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S,
Stuckler D, et al.;1; Financial crisis, austerity, and health in
Europe. The Lancet 13;381:1323–31.
6]. Gené-Badia J, Gallo P, Hernández-Quevedo C, García-Armesto
S.  Spanish health care cuts: Penny wise and pound foolish?
Health Policy 2012;106:23–8.
7]. Caballero Perea B, Villegas AC, Rodríguez JMD, Velloso MJG,
Vicente AMG, Cabrerizo CH, et al. Recommendations of the
Spanish Societies of Radiation Oncology (SEOR). Nuclear
Medicine & Molecular Imaging (SEMNiM), and Medical Physics
(SEFM) on 18F-FDG PET-CT for radiotherapy treatment planning
Rep  Pract Oncol Radiother 2012;17:298–318.
8]. Borràs JM, Colomer C, Soria P, López R. Priorities for cancer
control in Spain. Ann Oncol 2010;21:iii111–4.
9]. Herruzo I, Romero J, Palacios A. The white book of radiation
oncology in Spain. Clin Transl Oncol 2011;13:385–95.
0]. S´migielska M, Milecki P. Investment in radiotherapy
infrastructure positively affected the economic status of an
oncology hospital. Rep Pract Onco Radiother 2012;17:151–6.
1]. Lanni Jr TB, Grills IS, Kestin LL, Robertson JM. Stereotactic
radiotherapy reduces treatment cost while improving overall
survival and local control over standard fractionated
radiation therapy for medically inoperable non-small-cell
lung cancer. Am J Clin Oncol 2011;34:494–8.
2]. Levitt SH, Perez CA, Hui S, Purdy JA. Evolution of
computerized radiotherapy in radiation oncology: potential
problems and solutions. Int J Radiat Oncol Biol Phys
2008;70:978–86.
3]. Malicki J. The importance of accurate treatment planning,
delivery, and dose veriﬁcation. Rep Pract Oncol Radiother
2012;17:63–5.
4]. Van Loon J, Grutters J, Macbeth F. Evaluation of novel
radiotherapy technologies: what evidence is needed to assess
d rad
[1
[1
[1
Aguiló F, et al. [Cost comparison of three treatments for404  reports of practical oncology an
their clinical and cost effectiveness, and how should we get
it? Lancet Oncol 2012;13:e169–77.5]. Corn BW, Glatstein E. The most important question. Int J
Radiat Oncol Biol Phys 2009;74:985–6.
6]. MacReady N. The Promise of Protons in Cancer Therapy. JNCI
J  Natl Cancer Inst 2012;104:648–9.iotherapy 1 8 ( 2 0 1 3 ) 401–404
7]. Becerra Bachino V, Cots F, Guedea F, Pera J, Boladeras A,localized prostate cancer in Spain: radical prostatectomy,
prostate brachytherapy and external 3D conformal
radiotherapy]. Gac Sanit 2011;25:35–43.
